Shire Buys Pfizer's IBD MAdCAM-1 Candidate For Undisclosed Price
Executive Summary
Back on the product trail after its mega merger with Baxalta Inc, Shire PLC has bought global rights to Pfizer Inc.'s investigational biologic PF-00547659 for inflammatory bowel disease.